World's Best Scientists 2026 revealed!
Jean-Luc Harousseau

Jean-Luc Harousseau

D-Index & Metrics

Medicine

D-Index
130
Citations
75233
World Ranking
2462
National Ranking
63

Overview

Jean-Luc Harousseau is affiliated with the University of Nantes in France and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research is primarily focused on multiple myeloma, protein degradation and inhibitors, and cancer therapeutics, with additional work on amyloidosis and myeloproliferative neoplasms.

The scientist's notable recent papers include:

  • Comprehensive Review of AL amyloidosis: some practical recommendations, 2021, Blood Cancer Journal
  • Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update, 2022, Blood Cancer Journal
  • Requirements for operational cure in multiple myeloma, 2021, Blood
  • Potential future direction of measurable residual disease evaluation in multiple myeloma, 2023, Blood
  • A roadmap towards improving outcomes in multiple myeloma, 2024, Blood Cancer Journal

The frequent co-authors alongside Jean-Luc Harousseau are:

  • Mohamad Mohty
  • Florent Malard
  • Hervé Avet-Loiseau
  • Tamás Zelei
  • Paul Keown

The scientist's work appears predominantly in the following publication venues:

  • Blood Cancer Journal
  • Blood
  • Journal of Medical Economics
  • Value in Health
  • Cancer Treatment Reviews

Jean-Luc Harousseau's research covers a variety of topics, including:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Cancer therapeutics and mechanisms
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Ubiquitin and proteasome pathways
  • Cancer Treatment and Pharmacology

Their subfields of study include molecular biology, hematology, oncology, genetics, and epidemiology. The breadth of topics and consistent publication in leading journals indicate a sustained focus on hematologic malignancies and related therapeutic strategies.

Best Publications

  • A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

    Michel Attal;Jean-Luc Harousseau;Anne-Marie Stoppa;Jean-Jacques Sotto

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

    Paul G. Richardson;Pieter Sonneveld;Michael W. Schuster;David Irwin

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's Lymphoma

    T Philip;C Guglielmi;A Hagenbeek;R Somers

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Jean-Luc Harousseau;Thierry Facon;François Guilhot

  • Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

    Michel Attal;Valerie Lauwers-Cances;Gerald Marit;Denis Caillot

  • Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.

    Thierry Facon;Jean Yves Mary;Cyrille Hulin;Lotfi Benboubker

  • Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

    Michel Attal;Valerie Lauwers-Cances;Cyrille Hulin;Xavier Leleu

  • Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

    Philippe Moreau;Halyna Pylypenko;Sebastian Grosicki;Ievgenii Karamanesht

  • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome

    Hervé Avet-Loiseau;Michel Attal;Philippe Moreau;Catherine Charbonnel

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression

    Robert Z. Orlowski;Arnon Nagler;Pieter Sonneveld;Joan Bladé

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

    Michel Attal;Jean-Luc Harousseau;Serge Leyvraz;Chantal Doyen

  • Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia

    Guilhot F;Chastang C;Michallet M;Guerci A

  • Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myélome 9502 randomized trial

    Philippe Moreau;Thierry Facon;Michel Attal;Cyrille Hulin

  • Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.

    Jean-Luc Harousseau;Michel Attal;Hervé Avet-Loiseau;Gerald Marit

  • Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

    Paul Gerard Richardson;Pieter Sonneveld;Michael Schuster;David Irwin

  • Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Commentary

    Giampaolo Merlini;Michel Attal;Jean-Luc Harousseau;Serge Leyvraz

Frequent Co-Authors

Michel Attal
Michel Attal Janssen (Belgium)
Philippe Moreau
Philippe Moreau University of Nantes
Thierry Facon
Thierry Facon Centre Hospitalier Régional et Universitaire de Lille
Régis Bataille
Régis Bataille University of Angers
Denis Caillot
Denis Caillot Grenoble Alpes University
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Norbert Ifrah
Norbert Ifrah Grenoble Alpes University
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in medicine doesn’t always require attending medical school. There are a range of online degrees and alternative healthcare career pathways that offer both flexibility and affordability.

For those interested in healthcare leadership or management, consider exploring cheapest mha programs online. These programs provide a cost-effective way to enter healthcare administration. Before enrolling, it’s wise to compare tuition and fees. You can get a clearer picture of potential expenses by reviewing average masters in healthcare administration cost.

If you aspire to advanced practice in nursing, pursuing the cheapest dnp online programs may help you earn a Doctor of Nursing Practice degree without breaking the bank. Pharmacists, on the other hand, can check out flexible and affordable options among online pharm d online programs.

By exploring these related pathways, you can find a healthcare career that aligns with your interests, goals, and budget.

Best Scientists Citing Jean-Luc Harousseau

Trending Scientists

Recently Published Articles